Printer Friendly

Lamotrigine rivals Lithium in Effectiveness for Acute Mania. (Randomized, Controlled Trial).

ATLANTA -- Lamotrigine appeared as effective and well tolerated as lithium for the treatment of acute mania in a randomized, double-blind, controlled trial reported by Dr. Liviu Ichim at the annual meeting of the American Academy of Clinical Psychiatrists.

These findings were somewhat at odds with earlier findings from open trials and case reports, which had suggested that lamotrigine has more antidepressant than antimanic properties, said Dr. Ichim of the University of Witwatersrand in Johannesburg, South Africa.

Lamotrigine, a novel anticonvulsant, appears to have diverse mechanisms of action, including inhibition of the release of the excitatory neurotransmitter glutamate, calcium channel blockade, and an effect on voltage-sensitive sodium channels, which are believed to play a role in bipolar disorder.

The study, which received the George Winokur Clinical Research Award from the AACP, involved 30 patients who were hospitalized for acute mania and randomized to receive lamotrigine (titrated up to 100 mg/day) or lithium (400 mg/day) for 4 weeks. Most had had two or more prior episodes and were severely ill when they entered the study.

Patients also received lorazepam (4-12 mg/day) and biperidin (2-6 mg/day) as needed for control of aggression and acute dystonia, he said.

Changes in various measures of illness severity were comparable and highly significant with both drugs: Mania Rating Scale scores, for example, declined from 31.6 to 13.1 with lithium and from 37.4 to 14.3 with lamotrigine. Global Assessment of Functioning scores rose from around 45 to about 60, and there were no significant differences in Clinical Global Impression of Severity of Illness or Improvement scores between the groups, Dr. Ichim said.

The use of lorazepam was comparable whether lithium or lamotrigine were used, and biperiden use was negligible.

By the end of the study, "patients were better but not well," he said.

No significant adverse effects were seen in either group. In addition, there were no rashes in the lamotrigine group even though titration had been more rapid than the manufacturer advises, Dr. Ichim said.
COPYRIGHT 2001 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Sherman, Carl
Publication:Clinical Psychiatry News
Geographic Code:1USA
Date:Dec 1, 2001
Previous Article:Antiepileptic Drugs Disrupt Reproductive Function. (Monitor Metabolic, Endocrine Effects).
Next Article:St. John's Wort Labels often lead to more Questions, Few Answers. (What to Ask When Comparing Products).

Related Articles
Lamotrigine Prevents Mania Relapse in Bipolar I Disorder.
Depression Doesn't Impair Effectiveness Of Olanzapine for Acute Mania. (Olanzapine Treatment).
Clarifications. (Opinion).
Try Antipsychotic with Mood Stabilizer for Mania. (Monotherapy often Inadequate).
Both lamotrigine, lithium delay relapse of bipolar disorder. (Two International, Open-Label Studies).
Lamotrigine approval for bipolar I hailed as a first: like 'mirror image of lithium'; drug helps prevent depressive episodes.
Lithium has little effect on Mania.
Small study: tamoxifen may lift mania in bipolar.
Lamotrigine, lithium effective--for a while.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters